Gebrael, G., Jo, Y., Ozay, Z. I., Lin, E., Sayegh, N., Ostrowski, M., Nandakumar, V., Chehade, C. H., Ji, R., Murdock, E., Campbell, P., Thomas, V. M., Gupta, S., Maughan, B. L., Swami, U., Agarwal, N. (2026). Treatment patterns and outcomes with second line (2L) therapies in patients (pts) with advanced urothelial carcinoma (aUC) previously treated with first line (1L) enfortumab vedotin (EV) with pembrolizumab (pembro).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.676